Symptomatic venous thromboembolism in cancer patients treated with chemotherapy - An underestimated phenomenon

Hans-Martin M. B. Otten, Joost Mathijssen, Hugo ten Cate, Marcel Soesan, Marijke Inghels, Dick J. Richel, Martin H. Prins

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: The exact incidence of venous thromboembolism (VTE) in cancer patients is unknown, partly because of confounding factors. Prophylactic treatment is warranted in surgical patients with cancer because of a high incidence of VTE. We performed a retrospective study to evaluate if the same applies for cancer patients treated with chemotherapy. Methods: The medical records of 206 consecutive patients with malignancy, treated with chemotherapy, were identified. The kind of malignancy and chemotherapeutic treatment were recorded, as was the date of treatment. The records were reviewed for other risk factors for VTE, and were searched for proved deep venous thrombosis or pulmonary embolism. Results: Of those 206 patients, 15 (7.3%) had proved VTE during or within 3 months after chemotherapeutic treatment. The annual incidence was 10.9%. The incidence of VTE was specifically high in the 39 patients treated with a combination of fluorouracil and leucovorin calcium because of colorectal cancer (6 [15%] of the patients were affected). The occurrence of VTE in the latter group of patients was not influenced by factors such as surgery, central venous catheters, or tumor load. Conclusions: The annual incidence of VTE in patients treated with chemotherapy was high, specifically in patients with colorectal cancer treated with fluorouracil-leucovorin. If these observations are confirmed, trials to evaluate the use of prophylactic anticoagulant treatment should be conducted
Original languageEnglish
Pages (from-to)190-194
JournalArchives of Internal Medicine
Volume164
Issue number2
DOIs
Publication statusPublished - 2004

Cite this